Recently, companion diagnostics with nuclear medicine techniques have been anticipated as more suitable means than biopsy for predicting treatment efficacy. The anti-cancer effect of capecitabine, an orally administered chemotherapeutic agent activated by thymidine phosphorylase (TP), is positively associated with tumor TP expression levels. This study aimed to assess whether TP imaging using a radiolabeled uracil derivative, 
Introduction
Molecularly targeted drugs such as gefitinib and trastuzumab have been widely used in cancer treatment. To select patients expected to respond to these medicines, in vitro companion diagnostics have been used in clinical practice to assess gene mutations or protein expression before administration.
Companion diagnostics also decrease unnecessary adverse drug reactions while enabling patient stratification and facilitating drug development. Currently, biopsy samples or surgical specimens are used for in vitro companion diagnostics in clinical practice. However, several studies have evaluated companion diagnostics with imaging modalities (1) (2) (3) . The folate receptor imaging agent Tc-etarfolatide had higher sensitivity and specificity for the non-invasive detection of vintafolide-susceptible metastatic cancer foci than folate receptor immunohistochemistry using biopsy samples, suggested to result from changes in folate receptor expression over time or the heterogeneity of folate receptor expression among cancer lesions. Therefore, to avoid repeated biopsies and correctly evaluate the expression of target proteins difficult to examine with limited samples (e.g., the folate receptor), radiopharmaceutical companion diagnostics are more suitable than in vitro companion diagnostics. Additionally, other imaging agents such as Capecitabine, an orally bioavailable drug and the prodrug of 5-fluorouracil, is a broadly used anticancer drug for colorectal, breast, and stomach cancer. It produces serious adverse reactions including hand-foot syndrome, diarrhea, and bone marrow suppression (6, 7) , and tumor response rates vary from 20-50% (8) (9) (10) . Thymidine phosphorylase (TP), which is overexpressed in various tumors, catalyzes the reversible conversion of thymidine to thymine and 2-deoxy-D-ribose-1-phosphate (11) . Capecitabine is absorbed through the intestine and metabolized to doxifluridine by carboxylesterases and cytidine deaminases in the liver. Doxifluridine is metabolized to active forms by TP in the liver and tumor tissues (12) (Suppl. Fig. 1 ). Capecitabine-based chemotherapies have been reported to be more effective in tumors expressing high TP levels (13) (14) (15) (16) . However, in these studies, tumor TP expression levels were determined immunohistochemically in surgical specimens or biopsy samples. TP expression is heterogeneous even in primary tumors (17) , differs between tumor and stromal cells and between the primary lesion and metastatic foci (18) , and is affected by chemotherapy (e.g., taxanes, cyclophosphamide, anthracycline, and platinum) and radiotherapy (19) (20) (21) (22) (23) 
Materials and Methods

Cell cultures
The human colorectal cancer cell lines HCT116, WiDr, and DLD-1 were obtained from American Type Culture Collection and cultured in McCoy's 5A, MEM, and RPMI1640 culture media, respectively, containing 10% fetal bovine serum and penicillin/streptomycin/neomycin at 37°C in 5% CO 2 .
All cell culture regents were purchased from Life Technologies Corporation (Carlsbad, CA).
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Cell viability assay
Cells were seeded at a density of 2×10 and then washed twice with ice-cold phosphate-buffered saline. After the tracer solution was removed, serum-free medium (1 mL) was added, and the cells were further incubated for 0.5, 1, and 2 h. Following incubation for uptake or efflux, the cells were washed twice with ice-cold phosphate-buffered saline and lysed in 0.5 M NaOH (0.5 mL). Radioactivity in each aliquot was measured using a gamma counter (ARC-7001, Hitachi Aloka Medical, Mitaka, Japan) and normalized against the total protein concentration. 
Capecitabine treatment
Capecitabine (Santa Cruz Biotechnology) was suspended in distilled water and orally administered (539 mg/kg/day) to tumor-inoculated mice for 5 days per week, as previously reported (29) .
Control tumor-inoculated mice were left untreated. To evaluate capecitabine antitumor effect, tumor size and body weight were measured twice per week. Tumor volume was calculated using a caliper according to the following equation: volume = height × width × depth × (π / 6). Relative tumor size was calculated by dividing the tumor volume on any given day by that on the first day of treatment.
Biodistribution studies
These studies were performed 15 days after inoculation. Under isoflurane/air anesthesia, saline 
Immunohistochemistry
After SPECT/CT scanning, the mice were euthanized by exsanguination under deep isoflurane anesthesia, and tumor tissues were excised. Tumor tissues were fixed in 15% formalin for 48 h, paraffin embedded, and sectioned at 4 μm. The sections were mounted on slides, deparaffinized, and rehydrated. Additionally, some sections were stained with hematoxylin-eosin using a standard protocol.
Statistical analysis
Data are presented as the mean ± standard error of the mean (SEM 
Results
Antiproliferative activity of doxifluridine in cancer cell lines
Because capecitabine is converted to doxifluridine in the liver and then to 5-fluorouracil by TP in tumor cells (Suppl. Fig. 1 ), we used doxifluridine in our in vitro assay. TP expression levels in HCT116 cells were higher than those in WiDr or DLD-1 cells (Fig. 2A) . HCT116 cells were more sensitive to doxifluridine treatment than WiDr and DLD-1 cells (Fig. 2B) . The doxifluridine IC 50 values for HCT116, WiDr, and DLD-1 cells were 26.4, 74.3, and 77.9 µM, respectively, suggesting that TP expression levels parallel the antiproliferative activity of doxifluridine in vitro. There was no statistically significant difference among IC 50 values for the three cell types. TP siRNA transfection dramatically downregulated TP expression in HCT116 cells (Fig. 2C) . After 50 μM doxifluridine treatment for 48 h, the viability of TP siRNA-transfected cells and negative control cells was 70.3 and 40.5%, respectively (P < 0.01) (Fig. 2D) .
Thus, downregulation of TP significantly inhibited doxifluridine anti-cancer activity. (Fig. 3) .
Effect of capecitabine in transplanted tumors
Intracellular
123
I-IIMU uptake and retention
To assess whether 123 I-IIMU could reflect TP expression differences among these cell lines, we performed intracellular uptake and retention studies. In HCT116 cells, 123 I-IIMU intracellular uptake increased with incubation time and was significantly higher than that in DLD-1 cells (Fig. 4A ). In the efflux assay, 30.7% of the radioactivity prior to removing the tracer solution was retained by HCT116 cells at 2 h after removal, whereas only 1.23% was retained by DLD-1 cells (Fig. 4B) .
I-IIMU uptake by transplanted tumors
We further examined the biodistribution of (Fig. 5A) . Radiotracer levels in other tissues were similar across groups (Suppl. Table 1 ). Additionally, radioactivity levels in thyroid gland and stomach, an indicator of in vivo deiodization, were low in these mice, as previously reported (24) . These data indicate a positive relation Fig. 2 ). To confirm the TP expression levels in HCT116 and DLD-1 cells, HCT116 and DLD-1 tumors were excised after SPECT/CT imaging, sectioned, and immunohistochemically stained (Fig. 6B) . High TP expression levels were observed in HCT116 tumors. Little TP expression was observed in DLD-1 tumors.
Discussion
Antiproliferative activity of doxifluridine in vitro was higher in HCT116 cells, which have higher TP expression levels, than in WiDr and DLD-1 cells (Figs. 2A and 2B ). TP downregulation significantly decreased sensitivity to doxifluridine (Figs. 2C and 2D) . A previous study showed that the antiproliferative by on August 28, 2017. For personal use only. jnm.snmjournals.org Downloaded from activity of doxifluridine in vitro was higher in HCT116 cells than in DLD-1cells (30) . Our results are consistent with this finding. We further investigated the relationship between the efficacy of capecitabine and TP expression levels in vivo (Fig. 3) . The efficacy of capecitabine has been found to correlate with TP mRNA levels and TP activity in previous studies (31, 32) . These studies showed that HCT116 cells were susceptible to capecitabine treatment, but neither WiDr nor DLD-1 cells were. Additionally, HCT116 had the highest TP activity among the three cell types, and DLD-1 had the lowest. Our results also correspond to these findings in vivo.
In vitro, intracellular uptake and retention of I-IIMU in mice (25, 27) . The radiolabelled tracers mainly accumulated in liver and small intestine, consist with our present results. Furthermore, we confirmed mRNA and protein by on August 28, 2017. For personal use only. jnm.snmjournals.org Downloaded from levels of TP in various mouse tissues (27) . We observed high TP expression in liver and intestine, which corresponded to the observed high accumulation of radiolabeled IIMU (Suppl. Table. 1 
Conclusion
We showed an association between TP expression levels determined non-invasively using Statistical analysis was performed using two-way analysis of variance followed by Tukey's multiple comparison test (*P < 0.05, †P < 0.01 vs. HCT116 non-treated). Results are expressed as mean ± SEM (n = 7-10).
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